Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

$ 23.50

4.8 (583) In stock

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques - ScienceDirect

Biomedicines, Free Full-Text

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 - ScienceDirect

Vaccines, Free Full-Text

Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2

COVID-19 vaccine - Wikipedia

Frontiers Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Omicron-specific booster may not be needed, U.S. monkey study finds

PDF) Beta variant COVID-19 protein booster vaccines elicit durable cross- neutralization against SARS-CoV-2 variants of concern in non-human primates

Vaccines, Free Full-Text